ArticleFrontiers in psychology2026
A prospective, single-center, quasi-experimental study protocol for evaluating the efficacy of stepwise Yalom group therapy in reducing depressive symptoms and interpersonal problems in Chinese female patients with depressive disorders.
Article in Frontiers in psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Depressive disorder is affecting significantly more women than men. It is often accompanied by interpersonal difficulties, which severely impair patients' social functioning. Individual interpersonal therapy can help improve interpersonal problems, but the implementation of individual therapy is more difficult than that of group therapy. This study aims to evaluate the efficacy of Yalom group therapy in reducing depressive symptoms and interpersonal difficulties among Chinese women with depressive disorders. Methods: A total of 90 participants will be allocated to either the intervention group or the control group. Inclusion criteria: ① Diagnosis of depressive disorder or recurrent depressive disorder according to the International Classification of Diseases, 10th Revision (ICD-10), confirmed by two attending physicians or above; ② Female sex; ③ Age ≥18 years and <60 years; ④ Ability to communicate verbally; ⑤ Hamilton Depression Scale-17 (HAMD-17) score ≥18; ⑥ No psychological treatment received within 6 months; ⑦ Voluntary participation with informed consent. Exclusion criteria: ① Current or planned physical therapy (e.g., electroconvulsive therapy, deep transcranial magnetic stimulation); ② Participation in other group or individual psychological therapy; ③ Comorbidity with severe conditions (e.g., severe personality disorders, substance abuse, neurological diseases); ④ Intellectual disability. The control group will receive 5 weeks of routine care and standard treatment. The intervention group will receive 5 weeks of stepwise Yalom group therapy plus routine care and standard treatment. Primary outcomes include improvements in depressive symptoms and interpersonal difficulties. Secondary outcomes include reductions in anxiety symptoms and enhancements in social functioning. Statistical analyses will be performed using SPSS 27.0. Data will be analyzed in accordance with statistical principles, and missing data will be handled using multiple imputation. Discussion: This study will enhance understanding of the application of Yalom group therapy in female patients with depressive disorders. As the first study in China to implement a full-course intervention for female inpatients with depressive disorders, it will provide insights into the utility of Yalom group therapy for mitigating disease severity and improving interpersonal outcomes in this population. Clinical trial registration: https://www.chictr.org.cn/, identifier ChiCTR2600116067.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.